Skip to content
Review Open access

Emerging roles of cannabinoid pathways in renal injury and repair

Jul 2026 · Frontiers in Pharmacology · Vol 17 · 0 citations · 160 references
Medicine

TL;DR

This mechanistic review examined the pharmacological actions of classic and emerging cannabinoid receptors on the renal system to identify potential therapeutic targets for kidney disease.

Abstract

Chronic kidney disease (CKD) is a significant health problem around the world. It can progress towards end-stage renal disease (ESRD), in which the current therapeutic options are dialysis and kidney transplant, which have several challenges in therapy compliance and finding a donor. There is a crosstalk between high blood pressure, diabetes, and obesity, which are the leading causes of CKD. The increased prevalence of these conditions, plus the ageing population, highlights the importance of finding new therapies to prevent and stop the progression of CKD. At the cellular level, CKD is characterized by the progressive loss of podocytes in the kidney glomeruli, reducing their filtration capacity. Other hallmarks of CKD are also part of acute kidney injury (AKI) pathogenesis, and both conditions are interlinked. The renal system expresses cannabinoid receptor types 1 and 2 (CB1 and CB2, respectively). There is evidence in animal models that targeting the cannabinoid receptors could modulate the progression of CKD and AKI. The role of cannabinoid signalling has not been sufficiently explored; several receptors that are not fully characterized have emerged as putative cannabinoid receptors (i.e., GPR55, GPR18, and GPR119), and some have been implicated in kidney pathophysiology. Moreover, cannabinoid receptors also interact and/or regulate other receptors (e.g., AT1, TRPV1, and PPARγ). Thus, there are several open questions regarding the role that cannabinoid signalling may play in the context of kidney diseases. In this mechanistic review, we examined the pharmacological actions of classic and emerging cannabinoid receptors on the renal system to identify potential therapeutic targets for kidney disease.

Read PDF

Similar papers

Review Sep 2026

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes

Investigating treatments for CKD possess anti-inflammatory properties that might contribute to their previously established clinical benefits, including renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocortico...

Katherine R. Tuttle, Mehmet Kanbay, Radica Z. Alicic et al. · 1 citation
Review Open access Sep 2026

Signaling pathways in the pathogenesis of diabetic kidney disease (review)

An overview of the key signaling pathways and molecular mediators that underlie typical pathophysiological processes in diabetic kidney disease is presented and central role of transforming growth factor-beta in activating various signaling pathways is noted.

O. A. Nagibovich, A. L. Kovalenko, O. S. Ketlinskaya · 0 citations
Editorial Open access Aug 2026

Navigating the nexus: synergistic challenges in diabetes, hypertension, and renal medicine

The studies assembled in Renal Failure address challenges from complementary perspectives, spanning acute clinical biomarkers, dialysis outcomes, nutritional epidemiology, cellular therapeutics, and epigenetic regulation.

Omar Ahmed, Hatem Ali, Shafi Malik · 0 citations
Review Open access Aug 2026

Pathophysiological mechanisms, potential biomarkers, and therapeutic interventions in diabetic nephropathy

The present review attempts to discuss the different stages of DN, the pathophysiological mechanisms involved in DN development and progression, and potential biomarkers and therapeutic approaches for the effective management of DN.

Kuldip Vyas, Abu Sufiyan Chhipa, Ayushi Chauhan et al. · 0 citations
Open access Sep 2026

Beta-caryophyllene reduces lung inflammation secondary to chronic kidney disease.

BACKGROUND Chronic kidney disease (CKD) causes millions of deaths and is a known risk factor for the development of other diseases. CKD has been associated with lung injury characterized by neutrophil infiltration and edema. Despite evidence that the lungs are distant organs affected in CKD, there is no treatment to im...

Bruna Barcelos de Simas, Maria Eduarda Sandin Milani Schütz, Gustavo Ferreira-Alves et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.